Objetivo Major advances in HIV/AIDS treatment regimens have fundamentally altered the natural history of the disease and sharply reduced HIV-related morbidity and mortality in countries where such treatments are accessible. The most notable advance is the use of combination antiretroviral therapy or ART. However, ART is unable to achieve virus eradication or “sterilizing cure”. Indeed, in most cases, viral rebound is observed after ART interruption. Thus, life-long treatment is currently needed to control HIV. Drug resistance, cumulative side effects and high cost, represent major drawbacks of such treatments. The persistence of HIV in treated patients results from the establishment of a viral reservoir insensitive to ART and poorly visible to the immune system. Thus, understanding HIV persistence and developing drugs able to flush out HIV, in order to achieve viral eradication or “sterilizing cure” remain outstanding challenges.Two main lines of research are being proposed. The first starts from the recent discovery by partners of this consortium of the immune-modulator Samhd1 as the cellular factor restricting HIV-1 infection in myeloid cells. We will explore a role for Samhd1 in immune activation and inflammation, and its impact on the balance between viral replication and persistence. To understand further HIV persistence, we will study the molecular mechanisms underlying post-integrative latency. The second aims at identifying and optimizing novel naturally occurring inducers of HIV reactivation. Additionally, a novel non-human primate model will be developed, allowing the study of viral persistence in vivo by tracking latently-infected cells.The project aims at (i) increasing knowledge on the contribution of immune activation and inflammation to HIV persistence (ii) deciphering the cellular and molecular mechanisms of viral persistence (iii) translating this basic knowledge into novel targets to achieve a cure for HIV/AIDS. Ámbito científico natural sciencesbiological scienceszoologymammalogyprimatologysocial sciencessociologydemographymortalitymedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistance Programa(s) FP7-HEALTH - Specific Programme "Cooperation": Health Tema(s) HEALTH.2012.2.3.2-3 - Prevention and treatment for HIV/AIDS, malaria and tuberculosis Convocatoria de propuestas FP7-HEALTH-2012-INNOVATION-1 Consulte otros proyectos de esta convocatoria Régimen de financiación CP-FP - Small or medium-scale focused research project Coordinador CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS Aportación de la UE € 1 482 188,36 Dirección RUE MICHEL ANGE 3 75794 Paris Francia Ver en el mapa Región Ile-de-France Ile-de-France Paris Tipo de actividad Research Organisations Contacto administrativo Jocelyn Mere (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (4) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo INSTITUT PASTEUR Francia Aportación de la UE € 929 651,84 Dirección RUE DU DOCTEUR ROUX 25-28 75724 Paris Ver en el mapa Región Ile-de-France Ile-de-France Paris Tipo de actividad Research Organisations Contacto administrativo Marie-Laure Rosso (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos UNIVERSITAET ULM Alemania Aportación de la UE € 822 679,60 Dirección HELMHOLTZSTRASSE 16 89081 Ulm Ver en el mapa Región Baden-Württemberg Tübingen Ulm, Stadtkreis Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Frank Gleixner (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS Suiza Aportación de la UE € 895 220,00 Dirección RUE DU BUGNON 21 1011 Lausanne Ver en el mapa Región Schweiz/Suisse/Svizzera Région lémanique Vaud Tipo de actividad Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Contacto administrativo Angela Ciuffi (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos PHARIS BIOTEC GMBH Alemania Aportación de la UE € 900 114,20 Dirección FEODOR LYNEN STRASSE 31 30625 HANNOVER Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Birgit Gillmann (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos
